Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 218

CBD Blood Pressure Research and Development Cannabinoids 218

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Project CBD

AUGUST 6, 2019

The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. None of the participants had been using any cannabinoid-based products prior to this study.

CBD 177

CBD Blood Pressure Research and Development Cannabinoids 177

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. The study, led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics , found anxiety was among the top three reasons for a medicinal cannabis prescription. The authors note, however, that the data doesn’t include patient outcomes. 11 May 2022.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

JULY 8, 2021

Seeks To Identify Novel Cannabinoids For Therapeutic Use. The intended purpose of these studies is to provide data that will feed into the cbdMD Therapeutics research pipeline. This safety data will support the ensuing preclinical trials in humans to explore the efficacy of the cannabinoids. CHARLOTTE, N.C.–(BUSINESS

Research and Development 111

Research and Development Pets Cannabinoids eCommerce 111

The Cannigma

JUNE 14, 2021

‘Junk’ cannabis ‘ill-suited for clinical trials’. The cannabis grown at the University of Mississippi “is junk, ill-suited for clinical trials, and genetically closer to hemp than the marijuana available from dispensaries and used by Americans nationwide,” according to the lawsuit. A promise made years ago.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

The Cannigma

JANUARY 13, 2023

Edibles won’t produce the same experience, but topicals may be able to help, too. A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. headaches per month.

Terpenes 132

Terpenes Strains THC Treatment 132

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. Types of Research.

Research and Development 108

Research and Development Data THC Clinical Trials 108

Cannabis Law Report

SEPTEMBER 20, 2021

CB4 products are formulated based on the latest medical evidence and come in convenient dosage forms that deliver effective levels of cannabinoids. The products leverage pharmaceutical technology to maximize performance and safety. CB4 Relief, the THC free CBD softgels formulated with VESIsorb® technology will be available in early November.

Clinical Trials 52

Clinical Trials Pharmaceutical Data Patients 52

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. For more information, visit www.inmedpharma.com. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

The two active cannabinoids in marijuana are cannabidiol (CBD) and tetrahydrocannabinol (THC), the latter of which causes psychoactive effects while the former does not. This system naturally produces cannabinoids in the bloodstream, but chronic stress, anxiety, and other stimuli can stifle the production of natural endocannabinoids.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

MAY 29, 2022

Celebrated author Michael Pollan has published two bestselling books on the topic: How to Change Your Mind and This is Your Mind on Plants. Clinical Trials and Human Subject Protections. FDA’s approval of an IND will also require sufficient evidence that the trial will be safe for human subjects.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

TheAnswerPage

JANUARY 11, 2022

and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ In addition, if clinicians are not well informed about the health effects of cannabinoid-based products, clinicians will not be able to optimally treat their patients. million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

Greencamp

FEBRUARY 2, 2019

Even though cannabis and cannabinoid-derived pharmaceuticals are both frequently used by HIV/AIDS patients, several studies show that something interesting happens when cannabis is consumed. It will be the biggest and most comprehensive research on this topic to date, and it will include 400 HIV patients from Florida. 2016 ( 3 ).

Marijuana 110

Marijuana Therapy Cannabinoids Patients 110

Greencamp

AUGUST 16, 2018

Exploring the available research on ALS and cannabinoids. The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. The first study I will reference is from 2006, conducted on mice.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Canna Care Docs

DECEMBER 16, 2020

Among the 100-plus chemicals called cannabinoids in the cannabis plant, the two that are best known for their medicinal benefits are tetrahydrocannabinol (THC) and cannabidiol (CBD). Medical cannabis is available in any of the same forms as recreational cannabis—as smokable flower, edibles , tinctures, topical products , and more.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 108

Programs Research and Development Education Treatment 108

CannaTech

SEPTEMBER 16, 2018

Many healthcare practitioners possess a knowledge gap about cannabis, as their medical school curriculum didn’t include any information on the topic. Over time extended clinical trials will continue to map out the plant’s therapeutic effects, supporting it as an alternative medicine offering relief for a long list of conditions.

Education 66

Education Medicine Clinical Trials Patients 66

Weedistry

MARCH 11, 2019

There are already devout fans, some boldfaced, who are drawn to CBD topical products largely for their pain-relieving properties. There are studies, she said, showing that for pain relief, CBD works best within the plant’s cannabinoid system, meaning that combinations of compounds are more effective than isolated ones. Capobianco said.

Oil 40

Oil CBD Wellness and Beauty Clinical Trials 40

CannaMD

OCTOBER 7, 2019

In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents. While scientists are still searching for a definitive explanation, researchers with Cannabis and Cannabinoid Research have an interesting theory. Believe it or not, science says: YES. And the coolest part?

Marijuana 105

Marijuana Cannabinoids Patients Conditions 105

The Herb Collective

JUNE 3, 2018

Applied topically, the product counters the overproduction of abnormal skin cells that cause irritation on the surface of the skin. The pharmacological profile of cannabinoids is similar to antipsychotic drugs and may therefore be a less expensive option for treating a condition such as Schizophrenia.

Oil 56

Oil CBD Blood Pressure Chronic Pain 56

The Cannigma

APRIL 8, 2021

Yeah, there are thousands of strains, but those thousands of strains, but those thousands of strains only make let’s say one or two of 60 cannabinoids in abundance. Half of those cannabinoids of plant doesn’t make or three quarters because they’re byproducts. This is by nature of the way we consume cannabinoids.

Medicine 108

Medicine Cannabinoids Cannabis THC 108

Cannabis Law Report

JULY 12, 2019

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Clinical toolkits to help navigate patient assessment and follow-ups.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ). Data collection. One coder then independently coded the entire dataset and entered the data into NVivo v12. 2016 ; Sznitman et al.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 17, 2019

Retailers such as Walgreens, CVS, Rite Aid, Kroger, Safeway, Nordstrom, and DSW are selling or plan to sell CBD-infused topical lotions, cosmetics, and even edibles where they are legally able to do so. THC is just one of the cannabinoids in the Cannabis sativa L. the form the finished product can take (edibles, topicals, etc.).

Law 40

Law Seed-To-Sale Hemp Recreational 40

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Harris has written a variety of books that touch on the topics of consciousness, spirituality, and psychedelics. Rick Doblin, Ph.D,

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51